Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil

Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil

Abstract INTRODUCTION: Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil. METHODS: A decision model estimated the life expectancy and costs of six diagnostic-therapeutic s...

Full description

Bibliographic Details
Main Authors: Tália Santana Machado de Assis, Ana Rabello, Gláucia Cota, Guilherme Loureiro Werneck, André Luís Ferreira de Azeredo-da-Silva
Format: Article
Language:English
Published: Sociedade Brasileira de Medicina Tropical (SBMT) 2019-04-01
Series:Revista da Sociedade Brasileira de Medicina Tropical
Subjects:
Visceral leishmaniasis
Cost-effectiveness
Diagnosis
Therapy
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822019000100638&lng=en&tlng=en
Description
Summary:Abstract INTRODUCTION: Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil. METHODS: A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies. RESULTS: IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year. CONCLUSIONS: These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.
ISSN:1678-9849

Similar Items